论文部分内容阅读
[目的]观察脾肾双补方联合MVP化疗方案治疗肺癌疗效。[方法]使用随机平行对照方法,将120例住院及门诊患者按掷骰子法随机分为两组。对照组56例MVP化疗方案,MMC丝裂霉素6~8mg/m2第1d静注;VDS 3mg/(m2.d)第1d与第8d静注;DDP(顺铂)50mg/(m2.d)第3~4d,静注。治疗组64例脾肾双补方,党参、黄芪、黄精各20g,山萸肉、女贞子、丹参各15g,巴戟天、干地黄各10g,鸡血藤30g,大枣10枚。痰湿盛减鹿角胶、干地黄,加云苓、陈皮、清半夏、竹茹;虚热盛减巴戟天,加玄参、知母),1剂/d,水煎200mL,早晚饭后温服。MVP化疗方案治疗同对照组。连续治疗21d为1疗程。观测临床症状、癌灶缓解、生存质量、生存期、不良反应。连续治疗2疗程(42d),判定疗效。[结果]治疗组显效18例,有效29例,无效17例,总有效率73.43%。对照组显效7例,有效23例,无效26例,总有效率53.57%。治疗组疗效优于对照组(P<0.01)。癌灶缓解率治疗组优于对照组(P<0.05)。生存质量疗效治疗组优于对照组(P<0.01)。生存期疗效治疗组优于对照组(P<0.05)。[结论]脾肾双补方联合MVP化疗方案治疗肺癌效果显著,值得推广。
[Objective] To observe the efficacy of spleen and kidney double-tonic combined with MVP chemotherapy in the treatment of lung cancer. [Methods] Using randomized parallel control method, 120 inpatients and outpatients were randomly divided into two groups according to the method of dice. 56 cases in the control group were treated with MVP chemotherapy, MMC MMC 6 ~ 8 mg / m2 intravenously on the 1st day, VDS 3 mg / (m2.d) on the 1st and 8th days, DDP (cisplatin) 50 mg / (m2.d ) 3 ~ 4d, intravenous injection. Treatment group, 64 cases of spleen and kidney Shuang Bu Fang, Codonopsis, Astragalus, Polygonatum each 20g, cornus, Ligustrum lucidum, Salvia 15g, Morinda officinalis, dried rehmannia each 10g, Millettia 30g, jujube 10. Phlegm dampness antler, dry yellow, add Yunling, dried tangerine peel, clear Pinellia, Zhuru; Lusheng Sheng Morinda, plus Scrophulariaceae, Anemarrhena), 1 / d, decoction 200mL, breakfast and dinner After warm clothes. MVP chemotherapy treatment with the control group. Continuous treatment of 21d for a course of treatment. Observation of clinical symptoms, remission, quality of life, survival, adverse reactions. Continuous treatment of 2 courses (42d), determine the efficacy. [Result] In the treatment group, 18 cases were markedly effective, 29 cases were effective, 17 cases were ineffective, and the total effective rate was 73.43%. The control group was markedly effective in 7 cases, effective in 23 cases, ineffective in 26 cases, the total effective rate was 53.57%. The treatment group than the control group (P <0.01). The remission rate of the treatment group was better than that of the control group (P <0.05). The quality of life effect treatment group was better than the control group (P <0.01). Survival efficacy of treatment group than the control group (P <0.05). [Conclusion] The treatment of lung cancer with spleen and kidney double-tonic combined with MVP chemotherapy is effective and worthy of promotion.